TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03587766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Drug: fexinidazole (FEXI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Drug: fexinidazole (FEXI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Drug: fexinidazole (FEXI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Drug: fexinidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Drug: fexinidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Drug: fexinidazole
Study: NCT00421655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazax
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.
Study: NCT04377854

Intervention type: OTHER
Intervention: Observation. No intervention per se.
Description: Observation. No intervention (no collection of blood).

Intervention type: OTHER
Intervention: Observation. No intervention per se.
Description: Observation. No intervention (no collection of blood).

Intervention type: OTHER
Intervention: 2) Observation and collection and of blood sample
Description: All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
Study: NCT03637647

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
Study: NCT03953131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00258752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-AST
Description: IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced IPT-AST
Description: Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School counseling
Description: Usual care consists of standard treatments, including individual counseling with guidance counselor.
Study: NCT03902366

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

Intervention type: BEHAVIORAL
Intervention: Neuroimaging
Description: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.

Intervention type: BEHAVIORAL
Intervention: Neuroimaging
Description: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.

Intervention type: BEHAVIORAL
Intervention: Neuroimaging
Description: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.

Intervention type: BEHAVIORAL
Intervention: Neuroimaging
Description: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Study: NCT03908567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tablet
Description: Oral dosing with tablets 3 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
Study: NCT02926222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is formulated as tablets of 40mg for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine is formulated as tablets of 40mg for oral administration.
Study: NCT03797482

Intervention type: PROCEDURE
Intervention: Intra-operative Tumor Tissue Biopsy
Description: The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
Study: NCT01007110

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: Docosahexaenoic Acid (DHA) from algal oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT03860766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
Study: NCT04429295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliomyelitis Vaccine bivalent types 1 and 3
Description: Pharmaceutical form:Oral suspension Route of administration: Oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rotavirus, live attenuated
Description: Pharmaceutical form:Oral suspension Route of administration: Oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rotavirus, live attenuated
Description: Pharmaceutical form:Oral suspension Route of administration: Oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study: NCT01609426

Intervention type: GENETIC
Intervention: DNA chip dedicated to the pharmacogenetic of steroids
Description: direct DNA extraction from peripheral blood cells
Study: NCT02988323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicovestibular Physio (CV PT)
Description: See description in CVPT arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Aerobic Exercise (LLAE)
Description: See description in LLAE arm

Intervention type: OTHER
Group type: OTHER
Intervention: Combination (LLAE and CV PT)
Description: See description in LLAE and CVPT arm
Study: NCT00701324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm B (3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm A (day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm A (day 15)
Study: NCT01981005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5424802
Description: Single oral doses followed by IV or oral administration of a 14C-labeled tracer
Study: NCT03189342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single task training
Description: The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual task training
Description: The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise-cognitive activity combined training
Description: The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
Study: NCT02349152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
Study: NCT03272503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 2mg/day (current) or 4 mg/day (study initiation)
Description: Pimozide 2mg tablets will be taken once daily.
Study: NCT03860766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
Study: NCT00159107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative behavior therapy
Description: Integrative behavior therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative behavior therapy
Description: Integrative behavior therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00826150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC-819
Description: Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Study: NCT03603561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS
Description: In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
Study: NCT02333422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS Neurofeedback
Description: The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
Study: NCT03717649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 2-stage venous cannula
Description: venous cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3-stage venous cannula
Description: venous cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated 3-stage venous cannula
Description: venous cannula
Study: NCT02393235

Intervention type: OTHER
Intervention: doppler ultrasonography
Description: Ovarian, uterine and spiral artery pulsatility index and resistance index will measure

Intervention type: OTHER
Intervention: doppler ultrasonography
Description: Ovarian, uterine and spiral artery pulsatility index and resistance index will measure

Intervention type: OTHER
Intervention: doppler ultrasonography
Description: Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
Study: NCT03272503

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Identical matching placebo lactose tablets
Study: NCT03030313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
Study: NCT01218347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg once daily for 21 days
Study: NCT03903718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules orally twice a day from Day 2 to Day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules orally twice a day from Day 2 to Day 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
Study: NCT01736189

Intervention type: DRUG
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection
Study: NCT03608059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG/PTCy
Description: low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard ATG
Description: in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard PTCy
Description: post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
Study: NCT04480606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: 47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
Study: NCT00240214

Intervention type: DRUG
Intervention: sirolimus
Description: Tablet, dosage is determined by trough level